[{"data":1,"prerenderedAt":231},["ShallowReactive",2],{"$f118i7n4i06ot3":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":23,"top_modalities":55,"top_diseases":81,"top_companies":111,"key_results":136,"trends":219,"previous_editions":228,"comparison":158,"highlighted_classes":229},1,"arvo-2026","ARVO","arvo","ARVO 2026",2026,"Ophthalmology","2026-11-15T10:10:42Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},4943,1218,298,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":20,"Phase 2\u002F3":21,"Phase 3":22},31,13,30,7,5,70,[24,28,32,34,36,40,44,46,49,52],{"name":25,"count":26,"share":27},"VEGFA",188,15,{"name":29,"count":30,"share":31},"VEGFB",72,6,{"name":33,"count":22,"share":31},"ANGPT2",{"name":35,"count":22,"share":31},"PGF",{"name":37,"count":38,"share":39},"GR",53,4,{"name":41,"count":42,"share":43},"C3b",26,2,{"name":45,"count":42,"share":43},"ESR1",{"name":47,"count":48,"share":43},"C3",23,{"name":50,"count":51,"share":43},"CHRM3",22,{"name":53,"count":54,"share":43},"CHRM4",21,[56,60,64,68,72,74,76,78],{"name":57,"count":58,"share":59},"Small molecules",715,59,{"name":61,"count":62,"share":63},"Non-antibody therapeutic proteins",224,18,{"name":65,"count":66,"share":67},"Monoclonal antibodies",209,17,{"name":69,"count":70,"share":71},"Bispecific antibodies",93,8,{"name":73,"count":70,"share":71},"Peptides",{"name":75,"count":30,"share":31},"Gene therapies",{"name":77,"count":59,"share":21},"Oligonucleotide and RNA therapeutics",{"name":79,"count":80,"share":39},"Carbohydrate, lipid and polymer therapeutics",46,[82,86,89,92,95,98,101,103,105,107],{"name":83,"count":84,"share":85},"exudative macular degeneration",134,11,{"name":87,"count":88,"share":85},"age-related macular degeneration (AMD)",131,{"name":90,"count":91,"share":71},"diabetic macular edema (DME)",99,{"name":93,"count":94,"share":71},"Glaucoma",96,{"name":96,"count":97,"share":21},"dry eye syndrome (DED)",64,{"name":99,"count":100,"share":21},"diabetic retinopathy (DR)",61,{"name":102,"count":59,"share":21},"geographic atrophy (GA)",{"name":104,"count":38,"share":39},"ocular hypertension",{"name":106,"count":80,"share":39},"Retinal atrophy",{"name":108,"count":109,"share":110},"retinitis pigmentosa (RP)",39,3,[112,115,117,119,121,124,126,128,131,133],{"name":113,"count":114,"share":20},"Roche",81,{"name":116,"count":22,"share":31},"Regeneron Pharmaceuticals",{"name":118,"count":100,"share":21},"Pfizer",{"name":120,"count":109,"share":110},"Merck",{"name":122,"count":123,"share":110},"Genentech",37,{"name":125,"count":54,"share":43},"Apellis Pharmaceuticals",{"name":127,"count":54,"share":43},"GSK",{"name":129,"count":130,"share":43},"AbbVie",20,{"name":132,"count":130,"share":43},"Alcon",{"name":134,"count":135,"share":43},"AstraZeneca",19,[137,144,153,161,167,173,182,189,196,202,210],{"title":138,"drug":139,"company":113,"phase":141,"disease":90,"finding":142,"url":143},"Automated quantification of retinal fluid volume in patients with DME: analysis of faricimab vs aflibercept in YOSEMITE\u002FRHINE",{"name":140,"slug":140},"faricimab","Phase 3","Median time to first IRF volume \u003C5 nL was week 72 for AFL Q8W after a median of 11 injections vs week 36 for FAR Q8W (hazard ratio [HR] 1.75 [95% CI: 1.49, 2.05]; P \u003C0.0001) and T&E (HR 1.75 [95% CI: 1.49, 2.06]; P \u003C0.0001) after a median of 7 and 6 injections, respectively.","https:\u002F\u002Fiovs.arvojournals.org\u002Farticle.aspx?articleid=2812937",{"title":145,"drug":146,"company":149,"phase":141,"disease":150,"finding":151,"url":152},"Interim Results of a Multicenter, Randomized, Controlled, Phase 3 Clinical Trial of a Single Subretinal Injection of ZVS101e in Patients with Bietti Crystalline Corneoretinal Dystroph",{"name":147,"slug":148},"ZVS101e","zvs101e","Chigenovo","Bietti crystalline dystrophy (BCD)","The mean change in the MLMT score was 0.62 points in the treated group versus -0.44 points in the control group (p=0.017).","https:\u002F\u002Fiovs.arvojournals.org\u002Farticle.aspx?articleid=2817753",{"title":154,"drug":155,"company":158,"phase":141,"disease":90,"finding":159,"url":160},"Intravitreal RC28-E, a Recombinant Fusion Protein with Simultaneous Inhibition of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor in patients with Diabetic Macular Edema: 52-week Results from a Randomized, Double-masked, Phase 3 Trial",{"name":156,"slug":157},"eflimrufusp alfa","eflimrufusp-alfa",null,"Analysis in moderately severe to severe non-proliferative diabetic retinopathy patients showed superior ≥3-step DRSS improvement with RC28-E vs aflibercept (27.8% vs 11.6% patients, respectively; nominal P = 0.0223).","https:\u002F\u002Fiovs.arvojournals.org\u002Farticle.aspx?articleid=2815873",{"title":162,"drug":163,"company":158,"phase":141,"disease":83,"finding":165,"url":166},"Pigment epithelial detachment outcomes with aflibercept 8 mg versus aflibercept 2 mg in the PULSAR trial: A 96-week post hoc analysis",{"name":164,"slug":164},"aflibercept","At W96, the proportion of patients with serous PED decreased by 29.2% (2q8), 37.5% (8q12) and 36.7% (8q16) from BL, with fewer active injections with 8q12 and 8q16 versus 2q8 (9.7 and 8.2 vs 12.8) in the overall population.","https:\u002F\u002Fiovs.arvojournals.org\u002Farticle.aspx?articleid=2813988",{"title":168,"drug":169,"company":125,"phase":141,"disease":102,"finding":171,"url":172},"Earlier treatment yields better outcomes: 5 years of pegcetacoplan treatment for geographic atrophy secondary to AMD",{"name":170,"slug":170},"pegcetacoplan","Eyes in the Early Treatment group demonstrated better outcomes: NSF GA growth was reduced by 31% with PM, preserving 3.87 mm 2 of retinal tissue (~2 disc areas), versus 26% and 1.93 mm 2 in the Delayed Treatment group.","https:\u002F\u002Fiovs.arvojournals.org\u002Farticle.aspx?articleid=2815008",{"title":174,"drug":175,"company":178,"phase":179,"disease":102,"finding":180,"url":181},"Time-to-event analysis of driving eligibility maintenance following treatment with avacincaptad pegol in patients with geographic atrophy",{"name":176,"slug":177},"avacincaptad pegol","avacincaptad-pegol","Astellas Pharma","Phase 2\u002F3","The risk probability of progressing to loss of driving eligibility in the study eye (≤60 letters) at 24 mths was 12.6% for ACP monthly or EOM vs 20.1% for sham, a 41% relative reduction in risk (hazard ratio [HR]: 0.59; 95% confidence interval [CI]: 0.34,1.02; nominal P =0.0594).","https:\u002F\u002Fiovs.arvojournals.org\u002Farticle.aspx?articleid=2813490",{"title":183,"drug":184,"company":113,"phase":186,"disease":90,"finding":187,"url":188},"Efficacy and safety of vamikibart in combination with ranibizumab in patients with DME: first results from the phase 2 BARDENAS trial",{"name":185,"slug":185},"vamikibart","Phase 2","VAM+RBZ showed a statistically significant difference in the adjusted mean BCVA change from baseline at W44\u002F48 of +12.8 letters versus +9.4 letters for RBZ ( P =0.063 with a pre-established nominal 0.1 significance level).","https:\u002F\u002Fiovs.arvojournals.org\u002Farticle.aspx?articleid=2813173",{"title":190,"drug":191,"company":158,"phase":186,"disease":87,"finding":194,"url":195},"Oral QA102 Reduces Drusen Volume and Geographic Area Growth in Intermediate Atrophic Age-Related Macular Degeneration",{"name":192,"slug":193},"QA102","qa102","Compared to placebo, the mean change in drusen volume was reduced by 29.6% for subjects receiving QA102 200 mg (p=0.357) and 59.2% for QA102 400 mg (p=0.089).","https:\u002F\u002Fiovs.arvojournals.org\u002Farticle.aspx?articleid=2815759",{"title":197,"drug":198,"company":158,"phase":186,"disease":90,"finding":200,"url":201},"Oral Tonabersat Connexin-43 Modulator for Eyes with Diabetic Macular Edema with Good Vision (DRCR Protocol AN)",{"name":199,"slug":199},"tonabersat","The mean (SD) change in CST from baseline to 6 months was -15 (55) µm in the tonabersat group and +5 (51) µm in the placebo group (adjusted mean difference: -16 [95% CI, -34 to 2], P=0.08).","https:\u002F\u002Fiovs.arvojournals.org\u002Farticle.aspx?articleid=2815872",{"title":203,"drug":204,"company":207,"phase":186,"disease":90,"finding":208,"url":209},"VERONA phase 2 clinical trial of bioerodible EYP-1901 (vorolanib intravitreal insert) versus aflibercept for diabetic macular edema (DME): Visual, anatomic, and angiographic outcomes",{"name":205,"slug":205,"named_as":206},"vorolanib","EYP-1901","EyePoint Pharmaceuticals","At W24, mean BCVA change from baseline was +7.1, +6.9, and +7.3 letters in the EYP-1901 2.7mg, 1.3mg, and afl arms, respectively.","https:\u002F\u002Fiovs.arvojournals.org\u002Farticle.aspx?articleid=2815874",{"title":211,"drug":212,"company":215,"phase":216,"disease":96,"finding":217,"url":218},"IVW-1001 ophthalmic eyelid wipe to treat dry eye patients, a Phase 1\u002F2a Trial",{"name":213,"slug":214},"IVW-1001","ivw-1001","IVIEW Therapeutics","Phase 1\u002F2","tCFS: 0.2% improved tCFS vs vehicle at Week 4 (study eye, p=0.0499) and Weeks 1–4 (fellow eye, p\u003C 0.05).","https:\u002F\u002Fiovs.arvojournals.org\u002Farticle.aspx?articleid=2815856",{"summary":220,"bullets":222},[221],"Small molecules were the most frequent modality (59% of drug-linked abstracts). VEGFA was the most frequent target (15%). Exudative macular degeneration was the most frequent disease (11%).",[223,224,225,226,227],"Roche had the largest company share (7% of drug-linked abstracts).","Bispecific antibodies accounted for 8% of drug-linked abstracts.","Non-antibody therapeutic proteins were the next most frequent modality (18%).","VEGFB was the next most frequent target (6%).","Age-related macular degeneration (AMD) was the next most frequent disease (11%).",[],[230],{"name":69,"count":70,"share":71,"previous_count":158,"previous_share":158,"direction":158},1794807930046]